HLB, Can a Former Samsung Biologics CEO Deliver FDA Approval? HLB has embarked on a sweeping management overhaul as it prepares to reattempt U.S. Food and Drug Administration (FDA) approval for its liver cancer drug rivoc

HLB has embarked on a sweeping management overhaul as it prepares to reattempt U.S. Food and Drug Administration (FDA) approval for its liver cancer drug rivoceranib.
#HLB #FDA #rivoceranib #liver #cancer #SamsungBiologics #itchosun #chosun #SouthKorea #Korea #NewsUpdate

K-New Drugs Poised for Global Success In the Year of the Blue Snake, 2025, there is growing anticipation about how domestic new drugs will perform in the global market.According to industry sources

K-New Drugs Poised for Global Success
#SouthKorea #biotech #drug #Rivoceranib #HLB

Is #Rivoceranib + #camrelizumab headed for #HCC @US_FDA approval? The near future will tell #LiverTwitter www2.onclive.com/view/fda-holds-pre-nda-m... via @onclive

@ILCAnews Drs. Tim Meyer @ucl and Katie Kelley @UCSFMedicine review the current state of #HCC systemic therapy #sorafenib #lenvatinib #cabozantinib #pembrolizumab #atezolizumab #bevacizumab #durvalumab #tremelimumab #camrelizumab #tislelizumab #rivoceranib #ilca22